HDL2 can inhibit further oxidative modification of partially oxidized LDL

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 3, 2010, Pages 229-234

  Sakuma, Nagahiko ^a   Saeki, Tomoaki ^a   Ito, Tatsuya ^a   Hibino, Takeshi ^a   Suzuki, Shogo ^a   Kunimatsu, Mitoshi ^b   Yamamoto, Koji ^a   Kitada, Syuichi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NAGOYA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Lipid hydroperoxide; Oxidized LDL

Indexed keywords

COPPER ION; HIGH DENSITY LIPOPROTEIN 2; LIPID HYDROPEROXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATE BUFFERED SALINE; COPPER; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN;

AGAR GEL ELECTROPHORESIS; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ELECTROPHORETIC MOBILITY; INCUBATION TIME; LIPOPROTEIN METABOLISM; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; BIOSYNTHESIS; BLOOD; HUMAN; IN VITRO STUDY; METABOLISM; OXIDATION REDUCTION REACTION; PHYSIOLOGY;

COPPER; ELECTROPHORESIS, AGAR GEL; HUMANS; LIPID PEROXIDES; LIPOPROTEINS, HDL2; LIPOPROTEINS, LDL; OXIDATION-REDUCTION;

EID: 77951186088     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.1495     Document Type: Article

References (40)

1. Kannel WB: The Framingham study: ITS 50-year legacy and future promise. J Atheroscler Thromb, 2000; 6: 60-66
2. Henriksen T, Mahoney EM, Steinberg D: Enhanced macrophage degradation of biologically modified low density lipoprotein. Arteriosclerosis, 1983; 3: 149-159
3. Morel DW, DiCorleto PE, Chisolm GM: Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis, 1984; 4: 357-364
4. Quinn MT, Parthasarathy S, Steinberg D: Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low density lipoprotein. Proc Natl Acad Sci USA, 1985; 82: 5949-5953
5. Quinn MT, Parthasarathy S, Fong LG, Steinberg D: Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA, 1987; 84: 2995-2998
6. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med, 1989; 320: 915-924
7. Schwartz CJ, Valente AJ, Sprague EA, Kelly JL, Nerem RM: The pathogenesis of atherosclerosis: an overview. Clin Cardiol, 1991; 14: 11-16
8. Wilson PW, Abbott RD, Castelli WP: High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis, 1988; 8: 737-741
9. Brown G, Algers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med, 1990; 323: 1289-1298
10. Gordon DJ, Rifkind BM: High density lipoprotein-the clinical implications of recent studies. N Engl J Med, 1989; 321: 1311-1316
11. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 1989; 79: 8-15
12. Sviridov D, Mukhamedova N, Remaley AT, Chin-Dusting J, Nestel P: Antiatherogenic functionality of high density lipoprotein: how much versus how good. J Atheroscler Thromb, 2008; 15: 52-62
13. Chander R, Kapoor NK: High density lipoprotein is a scavenger of superoxide anions. Biochem Pharmacol, 1990; 40: 1663-1665
14. Klimov AN, Gurevich VS, Nikiforova AA, Shatilina LV, Kuzim AA, Plavinsky SL, Teryukova NP: Antioxidative activity of high density lipoproteins in vivo. Atherosclerosis, 1993; 100: 13-18
15. Parthasarathy S, Barnett J, Fong LG: High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta, 1990; 1044: 275-283
16. Yoshikawa M, Sakuma N, Hibino T, Sato T, Fujinami T: HDL3 exerts more powerful anti-oxidative, protective effects against copper-catalyzed LDL oxidation than HDL2. Clinical Biochem, 1997; 30: 221-225
17. Yoshikawa M, Sakuma N, Hibino T, Tamai N, Sasai K, Yoshimata T, Jin-no Y, Kamiya Y: Strong synergistic antiperoxidative effects of HDL3 and ascorbic acid against copper-catalyzed LDL peroxidation. Biochim Biophys Acta, 1998 1406: 307-314
18. Sakuma N, Saeki T, Yajima K, Hibino T, Yoshida T, Mizuno H, Mukai S, Sakata S, Kunimatsu M, Kimura G: Both HDL3 and HDL2 exert a powerful anti-oxidative and protective effect against acceleration of oxidative modification of LDL by ascorbic acid. J Nutr Sci Vitaminol, 2005; 51: 75-79
19. Mackness MI, Durrington PN: HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis, 1995; 115: 243-253
20. Kondo A, Li J, Manabe M, Saito K, Kanno T, Maekawa M: Relationship between high-density lipoprotein-cholesterol and malondialdehyde-modified low-density lipoprotein concentrations. J Atheroscler Thromb, 2003; 10: 72-78
21. Eisenberg S: High density lipoprotein metabolism. J Lipid Res, 1984; 25: 1017-1058
22. Sakuma N, Lin C, Matsumoto Y, Ikeuchi R, Ichikawa T, Hirata H, Noguchi Y, Fujinami T: Changes of HDL subfraction concentration and particle size by intralipid in vivo. Atherosclerosis, 1988; 74: 91-98
23. Kappus H: Lipid peroxidation: Mechanisms, analysis, enzymology and biological relevance. In: Oxidative Stress. ed by Sies H. pp 273-310, Academic Press, London. 1985
24. Jürgens G, Hoff HF, Chisolm GM, Esterbauer H: Modification of human serum low density lipoprotein by oxidation-characterization and pathophysiological implications. Chem Phys Lipids, 1987; 45: 315-336
25. Esterbauer H, Jürgens G, Quenhenberger O, Koller E: Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J Lipid Res, 1987; 28: 495-509
26. Havel RJ, Eder HA, Bragdon JH: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest, 1955; 34: 1345-1353
27. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Oslon BJ, Klenk DC: Measurement of protein using bicinchoninic acid. Anal Biochem, 1985; 150: 76-85
28. Steinbrecher UP, Witztum JL, Parthasarathy S, Steinberg D: Decrease in reactive amino groups during oxidation or endothelial cell modification of LDL. Correlation with changes in receptor-mediated catabolism. Arteriosclerosis, 1987; 7: 135-143
29. Ohishi N, Ohkawa H, Miike A, Tatano T, Yagi K: A new assay method for lipid peroxides using a methylene blue derivative. Biochem Int, 1985; 10: 205-211
30. Ehara S, Naruko T, Shirai N, Itoh A, Hai E, Sugama Y, Ikura Y, Ohsawa M, Okuyama T, Shirai N, Yamashita H, Itabe H, Haze K, Yoshiyama M, Ueda M: Small coronary calcium deposits and elevated plasama levels of oxidized low density lipoprotein are characteristic of acute myocardial infarction. J Atheroscler Throm, 2008; 15: 75-81
31. Esterbauer H, Dieber-Rotheneder M, Waeg G, Striegl G, Jürgens G: Biochemical, structural, and functional properties of oxidized low-density lipoprotein. Chem Res Toxicol, 1990; 3: 77-92
32. Mackness MI, Arrol S, Abbott C, Durrington PN: Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis, 1993; 104: 129-135
33. Durrington PN, Mackness B, Mackness MI: Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol, 2001; 21: 473-480
34. Kuremoto K, Watanabe Y, Ohmura H, Shimada K, Mokuno H, Daida H: R/R genotype of human paraoxonase (PON1) is more protective against lipoprotein oxidation and coronary artery disease in Japanese subjects. J Atheroscler Thromb, 2003; 10: 85-92
35. Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM: The plasma PAF acetylhydrolase prevents oxidative modification of low density lipoprotein. J Lipid Mediat Cell Signal, 1994; 10: 53-56
36. Gardner AA, Reichert EC, Topham MK, Stafforini DM: Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein. J Biol Chem, 2008; 283: 17099-17106
37. Chen N, Liu Y, Greiner CD, Holtzman JL: Physiologic concentrations of homocysteine inhibit the human plasma GSH peroxidase that reduces organic hydroperoxides. J Lab Clin Med, 2000; 136: 58-65
38. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM: Mechanisms of disease: proatherogenic HDL-an evolving field. Nat Clin Pract Endocrinl Metab, 2006; 2: 504-511
39. Sakuma N, Saeki T, Kobayashi K, Mukai S, Sakata S, Mizuno H, Kato T, Kunimatsu M, Kimura G: Oxidatively modified HDL2 is superior to native HDL2 in providing cholesterol to lymphocytes. Atherosclerosis (Supplements), 2006: 528
40. Sakuma N, Saeki T, Ito T, Hibino T, Oba T, Kunimatsu M, Kimura G: Oxidized HDL2 is superior to native HDL2 in providing cholesterol to lymphocytes via apo B, E (LDL) receptors. Ther Res, 2007; 28: 1365-1370